The purpose of Myocrisin (sodium aurothiomalate) is to provide long-term therapeutic support by acting as a Disease-Modifying Antirheumatic Drug (DMARD), focusing exclusively on controlling the core pathology of chronic inflammatory conditions. Its primary application is the management of active, progressive rheumatoid disease.

---

This medication is commonly used in conditions like Active Progressive Rheumatoid Arthritis (RA) in adults and certain severe forms of Juvenile Idiopathic Arthritis (JIA). It is typically applied in clinical settings when the disease is persistently active and has not responded adequately to initial therapies. Myocrisin is applied in addressing symptom clusters related to chronic joint inflammation, including joint swelling, tenderness, and morning stiffness.

---

The primary therapeutic aim is to support the patient in maintaining a stable disease state and may assist with managing conditions characterized by episodic or fluctuating manifestations. This long-term benefit supports the management of symptoms that interfere with daily functioning, which may assist with maintaining stability during symptomatic periods.

“This therapeutic approach is primarily relevant in contexts marked by increased systemic discomfort, aiming to ease the overall symptom load for patients with active inflammatory disease.”

---

Quick Fact: Role in Managing Inflammatory Symptoms
Myocrisin helps address symptom clusters that interfere with daily functioning, including stiffness and persistent swelling associated with active arthritis.

Regulatory References

1. Health Products Regulatory Authority (HPRA) of Ireland

Myocrisin (sodium aurothiomalate) is an injectable disease-modifying anti-rheumatic drug (DMARD) whose use is governed by a strict eligibility profile based on official regulatory documents.

Populations for Whom Use is Prohibited

Use is contraindicated (must not be used) in patients with known hypersensitivity to gold compounds, as well as those with:

• Severe renal or hepatic disease.
• Diabetes or marked toxaemia.
• A history of blood dyscrasias (severe blood disorders), exfoliative dermatitis (serious skin disorder), or Systemic Lupus Erythematosus (SLE).

Eligibility Restrictions

• Pregnancy and Lactation: The medicine must not be used during pregnancy or by women who are breastfeeding, as the drug can cross the placenta and is excreted in breast milk.
• Age-Related: Use in paediatric patients (children) is not established due to a lack of data. The medicine requires extra caution when administered to elderly patients.
• Conditions Requiring Caution: Use requires special consideration in patients with a history of heart or brain circulatory issues, moderate renal or hepatic impairment, or uncontrolled hypertension.

Interactions with Other Medicines and Products

Myocrisin (sodium aurothiomalate) may interact with certain other medicinal products, which could potentially affect the way either drug works or increase the risk of adverse effects. It is essential to inform a healthcare provider of all prescription, non-prescription, and herbal medicines currently being taken.

Clinically Relevant Interactions

Specific medicines and drug classes noted to have documented interactions or requiring close monitoring when administered with Myocrisin include:

• Penicillamine: Concomitant use with this agent, which is used for rheumatoid conditions and heavy metal poisoning, is explicitly documented as a potential interaction and should generally be avoided due to safety concerns.
• Angiotensin-Converting Enzyme (ACE) Inhibitors: Co-administration with this class of heart medicines, which includes agents like captopril and enalapril, may pose a risk of a nitritoid reaction (characterized by flushing, dizziness, and hypotension).
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Certain NSAIDs, specifically Phenylbutazone/Oxyphenbutazone and Aspirin, are listed in official documents as potentially interfering with Myocrisin's action or having their own effects altered.

General Considerations

The safety of combining Myocrisin with cytotoxic drugs (chemotherapy agents) has not been conclusively established, and such combinations should be approached with caution. Caution is also advised when Myocrisin is used in the elderly population. The overall treatment plan may require dose adjustments or the selection of alternative medicines when these interactions are present, and this decision is to be made by the treating physician.

The mechanism of action for sodium aurothiomalate involves multiple cumulative effects at the cellular and biochemical level, focused on modulating chronic immune cell hyperactivity. The fundamental action involves the covalent chemical modification of proteins within immune cells, such as macrophages and T-lymphocytes. The gold ion ( Au^+) specifically targets sulfhydryl ( -SH) groups on these proteins, altering their structure and inhibiting their function. This modification leads directly to the suppression of key immune cell activities, resulting in diminished sustained pathological signaling.

A critical downstream effect is the inhibition of lysosomal enzymes released by inflammatory cells into the joint space. By limiting the activity of these destructive proteases, the mechanism reduces the potential for surrounding cartilage and connective tissue degradation from biochemical processes. The resulting physiological effect is dependent on a slow, cumulative mechanistic cascade; the gold compound must gradually accumulate to a sufficient concentration within the target cells. This accumulation leads to a systemic modulation of chronic autoimmune processes, which is a functional consequence of the mechanism’s slow onset.

Myocrisin (sodium aurothiomalate) is administered exclusively by deep intramuscular (IM) injection, typically into the gluteal muscle, and should be followed by a gentle massage of the area. This gold-containing compound is a disease-modifying anti-rheumatic drug (DMARD) used to manage active progressive rheumatoid arthritis and is not intended for self-administration. It must be given under the supervision of a physician experienced in chrysotherapy.

Administration Schedule

Therapy begins with a low initial test dose to assess tolerance, usually 10 mg for adults. The patient is required to remain under observation for approximately 30 minutes following the injection due to the potential for immediate adverse reactions.

Phase	Administration Schedule	Typical Adult Dose	Max Single Dose
Initial Treatment	Weekly injections	25–50 mg	50 mg
Maintenance	Gradually increased intervals (e.g., every 2 to 4 weeks)	25–50 mg	50 mg

• The weekly injections continue until a significant clinical response or major improvement is observed, or until the cumulative dose reaches approximately one gram (1,000 mg).
• If the condition improves, the dose interval is progressively extended to every two, three, and then four weeks, and may be continued indefinitely to prevent relapse.

Key Monitoring Requirements

Regular monitoring is crucial due to the risk of serious side effects. Before each injection, a physician must review recent laboratory work, including a complete blood count (CBC) with differential, a platelet count, and a urinalysis for protein, to detect any signs of toxicity. Treatment should be withheld if certain adverse changes, such as significant proteinuria or hematologic abnormalities, occur.

Myocrisin (sodium aurothiomalate) is a gold compound historically classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD), primarily used for the management of active, progressive rheumatoid arthritis (RA). Clinical evidence accumulated over decades established its efficacy in controlling disease activity and reducing the risk of long-term joint damage in a significant subset of patients.

Therapeutic Role and Efficacy

Clinical trials have shown that sodium aurothiomalate is a slow-acting drug, with therapeutic improvement typically expected after two to six months of treatment, or after a minimum cumulative dose is reached. It functions by suppressing the immune system, modulating key immune cells (such as macrophages), and inhibiting the release of inflammatory agents like cytokines. Its use was particularly notable in patients who did not respond adequately to initial therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

However, despite its established role, the introduction of newer, often better-tolerated, biological therapies and targeted synthetic DMARDs has led to a major shift in clinical practice. The use of injectable gold salts has progressively declined over the last two decades.

Current Status of Supply

The most significant recent development concerning Myocrisin is its discontinuation from worldwide supply. Its manufacture was permanently ceased in 2019. Consequently, no new patients are currently initiated on this treatment. Existing patients who were successfully maintained on Myocrisin have been advised by specialists to transition to suitable alternative therapies.

Aspect	Status/Finding
Efficacy	Established in historical trials for active RA; slow onset (2–6 months).
Mechanism	Immunosuppressive; inhibits macrophages and inflammatory cytokines.
Current Use	Discontinued globally in 2019; no new patients are initiated.

Common questions about Myocrisin (FAQ)

Q: Is Myocrisin the same as other arthritis medications?

A: No, official classifications identify Myocrisin as a Disease-Modifying Anti-Rheumatic Drug (DMARD) belonging to the gold compound group. While it is used to manage rheumatoid arthritis, its classification and chemical structure are distinct from newer therapies, such as biologic drugs or targeted synthetic DMARDs.

Q: How quickly does Myocrisin start working?

A: According to official documentation, Myocrisin is a slow-acting drug. The therapeutic benefits, such as a noticeable improvement in disease activity, are typically not expected immediately. Improvement commonly begins to appear two to six months after the initial course of treatment has been established.

Q: Are there any long-term effects of using Myocrisin?

A: Regulatory documents indicate that close and continual monitoring is mandated due to the potential for serious adverse reactions over time. Safety concerns are frequently cited as a factor leading to the discontinuation of treatment. Regular blood and urine tests are officially required to check for early signs of toxicity during extended use.

Q: Is Myocrisin used to treat conditions other than rheumatoid arthritis?

A: The official product information primarily lists its indication for managing active rheumatoid arthritis. Some regulatory documents also mention its use for treating a form of juvenile arthritis known as Still's disease. Approved uses are typically limited to these two conditions.

Q: What is the difference between Myocrisin and methotrexate?

A: Myocrisin is a gold compound DMARD. Methotrexate is classified as an immunosuppressive agent and traditional DMARD. Regulatory cautions exist because the safety of combining Myocrisin with other immunosuppressive or cytotoxic medicines has not been conclusively established. This is due to regulatory caution regarding the possibility of additive toxicities when combining such agents.

Q: What should I do if I get a rash after Myocrisin?

A: Official protocols state the importance of reporting symptoms like a rash (dermatitis) to the physician for evaluation before each scheduled injection. Since skin reactions are a known side effect of gold therapy, treatment may need to be temporarily withheld if signs of toxicity are observed.

Q: Is Myocrisin still widely used today?

A: No. Official announcements confirm that the manufacture of Myocrisin was permanently discontinued worldwide in 2019 due to a shortage of the active pharmaceutical ingredient. New patients are not initiated on this treatment.

Q: Does Myocrisin cause weight changes?

A: While general weight changes are not consistently listed among the most common effects, regulatory safety documents note that weight gain and swelling in the ankles or feet (edema) are potential, though rare, serious adverse effects. These effects may sometimes be associated with renal (kidney) toxicity.

Q: What are the alternatives to Myocrisin?

A: Following its discontinuation, official communications indicated that patients who were stable on Myocrisin were advised to switch to other treatments. Alternatives generally consist of other Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including newer biologics and targeted synthetic agents, as recommended by a treating specialist.

Q: Is it normal to feel tired after a Myocrisin injection?

A: General fatigue or tiredness is not consistently listed among the most common adverse events in official documents. However, the regulatory label does note the potential for a temporary vasomotor (nitritoid) reaction immediately following the injection, which is described as including flushing or dizziness.

Q: Can Myocrisin worsen existing stomach problems?

A: Official safety warnings list severe gastrointestinal issues, such as Ulcerative Enterocolitis and persistent, severe diarrhea, as serious potential adverse effects. These severe adverse effects may require the discontinuation of the medicine.

Q: How long does the effect of a Myocrisin injection last?

A: Pharmacokinetic data from regulatory sources show that the elimination half-life of the compound ranges from 6 to 25 days. This value indicates the rate at which the drug is eliminated from the body, which guides the typical injection intervals used in maintenance therapy.

Q: What information about Myocrisin is available from official regulatory bodies?

A: Government regulatory bodies provide essential information needed for safe and appropriate use. This includes the drug's approved indications, the necessary administration schedules, its full safety profile (side effects, warnings, contraindications), and required monitoring procedures.

Q: Does Myocrisin have a boxed warning?

A: Yes, the regulatory labeling in the United States for the active ingredient, gold sodium thiomalate, includes a Black Box Warning (Boxed Warning). This is used to draw attention to the serious and potentially fatal toxicities associated with the treatment, such as severe blood and kidney disorders.

Q: Can Myocrisin interact with herbal supplements?

A: Regulatory documents state that healthcare providers must be informed of all medicines being taken, including prescription, non-prescription, and herbal supplements. The safety of combining Myocrisin with certain agents, including supplements, has not always been definitively established.

Q: What does the term 'remission' mean in the context of Myocrisin?

A: In rheumatoid arthritis, remission refers to a period where the signs and symptoms of the disease are absent or minimal. Regulatory-related texts mention that while some patients may achieve clinical remission in response to gold therapy, the drug’s primary role is described as a disease-modifying agent that helps suppress pathological disease activity.

Q: Is Myocrisin a cure for the condition it treats?

A: No. Official documents specify that there is no evidence that gold compounds, including Myocrisin, are a cure for rheumatoid arthritis. Its therapeutic purpose is to control disease activity, suppress chronic inflammation, and help prevent progressive joint damage.

Q: What is the typical timeframe before knowing if Myocrisin is working?

A: Therapeutic improvement is not expected immediately, as this is a slow-acting drug. Patients typically begin to see effects after two to six months of treatment or once a certain cumulative dose is reached. Consistent monitoring by a physician is necessary throughout this timeframe.

Storage and Handling Requirements

Myocrisin (sodium aurothiomalate) must be stored in a cool, dry place, with the temperature maintained below 25 °C.

Constraint Type	Required Condition
Temperature	Store below 25 °C
Protection	Protect from light
Integrity Check	Discard if solution is darker than pale yellow

The medicine should be kept in its original ampoule until use and must be stored out of the reach of children. Do not use the injection past the printed expiry date (EXP).

Disposal

Unused, expired, or compromised Myocrisin must be disposed of safely. Disposal procedures for the solution and its packaging must adhere strictly to local regulations for pharmaceutical waste.